CureVac Competitors

CureVac (NASDAQ:CVAC) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares CureVac and Zoetis' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares CureVac and Zoetis' top-line revenue, earnings per share and valuation.

Zoetis has higher revenue and earnings than CureVac.

Insider and Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. Comparatively, 92.5% of Zoetis shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for CureVac and Zoetis, as reported by MarketBeat.

CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Zoetis has a consensus target price of $170.0833, suggesting a potential upside of 0.80%. Given Zoetis' stronger consensus rating and higher possible upside, analysts clearly believe Zoetis is more favorable than CureVac.

Summary

Zoetis beats CureVac on 9 of the 9 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares CureVac and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares CureVac and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than CureVac.

Insider and Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for CureVac and Vertex Pharmaceuticals, as reported by MarketBeat.

CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Vertex Pharmaceuticals has a consensus target price of $293.2083, suggesting a potential upside of 33.18%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than CureVac.

Summary

Vertex Pharmaceuticals beats CureVac on 10 of the 10 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares CureVac and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares CureVac and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than CureVac.

Insider and Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for CureVac and Regeneron Pharmaceuticals, as reported by MarketBeat.

CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Regeneron Pharmaceuticals has a consensus target price of $644.1739, suggesting a potential upside of 27.71%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than CureVac.

Summary

Regeneron Pharmaceuticals beats CureVac on 10 of the 10 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares CureVac and Takeda Pharmaceutical's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares CureVac and Takeda Pharmaceutical's top-line revenue, earnings per share and valuation.

Takeda Pharmaceutical has higher revenue and earnings than CureVac.

Insider and Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. Comparatively, 3.4% of Takeda Pharmaceutical shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for CureVac and Takeda Pharmaceutical, as reported by MarketBeat.

CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Given CureVac's stronger consensus rating and higher possible upside, equities analysts clearly believe CureVac is more favorable than Takeda Pharmaceutical.

CureVac (NASDAQ:CVAC) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Insider and Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for CureVac and Alexion Pharmaceuticals, as reported by MarketBeat.

CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Alexion Pharmaceuticals has a consensus target price of $153.4286, suggesting a potential downside of 7.87%. Given Alexion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alexion Pharmaceuticals is more favorable than CureVac.

Profitability

This table compares CureVac and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares CureVac and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than CureVac.

Summary

Alexion Pharmaceuticals beats CureVac on 10 of the 10 factors compared between the two stocks.

BeiGene (NASDAQ:BGNE) and CureVac (NASDAQ:CVAC) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Insider & Institutional Ownership

60.7% of BeiGene shares are held by institutional investors. Comparatively, 4.3% of CureVac shares are held by institutional investors. 9.0% of BeiGene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for BeiGene and CureVac, as reported by MarketBeat.

BeiGene currently has a consensus target price of $319.3750, suggesting a potential upside of 9.09%. CureVac has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Given BeiGene's stronger consensus rating and higher possible upside, equities research analysts plainly believe BeiGene is more favorable than CureVac.

Profitability

This table compares BeiGene and CureVac's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares BeiGene and CureVac's top-line revenue, earnings per share and valuation.

CureVac has lower revenue, but higher earnings than BeiGene.

Summary

BeiGene beats CureVac on 6 of the 9 factors compared between the two stocks.